Wedbush Analysts Reduce Earnings Estimates for Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Analysts at Wedbush dropped their FY2027 EPS estimates for Day One Biopharmaceuticals in a report released on Tuesday, May 7th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of $0.61 per share for the year, down from their previous estimate of $0.78. Wedbush has a “Outperform” rating and a $33.00 price target on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($2.67) per share. Wedbush also issued estimates for Day One Biopharmaceuticals’ FY2028 earnings at $2.42 EPS.

Several other equities analysts have also weighed in on DAWN. Needham & Company LLC restated a “buy” rating and set a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday. JPMorgan Chase & Co. increased their target price on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the company an “overweight” rating in a research report on Monday, April 22nd. HC Wainwright lowered their price target on shares of Day One Biopharmaceuticals from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Tuesday. Piper Sandler reiterated an “overweight” rating and issued a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Tuesday, March 26th. Finally, The Goldman Sachs Group decreased their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $37.67.

Day One Biopharmaceuticals Trading Down 0.2 %

DAWN stock opened at $16.38 on Thursday. Day One Biopharmaceuticals has a 1-year low of $9.67 and a 1-year high of $18.07. The stock has a market cap of $1.43 billion, a P/E ratio of -6.88 and a beta of -1.44. The stock’s fifty day simple moving average is $15.45 and its two-hundred day simple moving average is $14.20.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07).

Insider Buying and Selling

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 2,258 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the sale, the insider now owns 1,244,662 shares of the company’s stock, valued at approximately $18,981,095.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Samuel C. Blackman sold 2,258 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $34,434.50. Following the sale, the insider now directly owns 1,244,662 shares in the company, valued at $18,981,095.50. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Charles N. York II sold 2,666 shares of the stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $40,656.50. Following the completion of the sale, the chief financial officer now directly owns 277,754 shares in the company, valued at $4,235,748.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 195,247 shares of company stock valued at $3,376,817. Company insiders own 8.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Quest Partners LLC bought a new stake in Day One Biopharmaceuticals during the fourth quarter valued at $29,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Day One Biopharmaceuticals by 130.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after acquiring an additional 1,262 shares during the last quarter. Quintet Private Bank Europe S.A. grew its holdings in shares of Day One Biopharmaceuticals by 43.2% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock worth $48,000 after purchasing an additional 1,000 shares in the last quarter. Amalgamated Bank increased its position in shares of Day One Biopharmaceuticals by 35.7% in the third quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock worth $106,000 after purchasing an additional 2,268 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its stake in Day One Biopharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock valued at $147,000 after purchasing an additional 2,554 shares in the last quarter. 87.95% of the stock is currently owned by hedge funds and other institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.